Park Avenue Securities LLC Sells 6,893 Shares of Zoetis Inc. $ZTS

Park Avenue Securities LLC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 45.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 8,348 shares of the company’s stock after selling 6,893 shares during the quarter. Park Avenue Securities LLC’s holdings in Zoetis were worth $1,050,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ZTS. Vanguard Group Inc. boosted its position in shares of Zoetis by 1.0% during the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after buying an additional 419,777 shares during the last quarter. Norges Bank bought a new stake in Zoetis in the 2nd quarter worth about $809,491,000. Brown Advisory Inc. raised its position in Zoetis by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after buying an additional 250,829 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Zoetis by 14.6% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after acquiring an additional 550,859 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in Zoetis by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock valued at $620,595,000 after acquiring an additional 496,320 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.6%

Zoetis stock opened at $116.65 on Thursday. Zoetis Inc. has a 52-week low of $113.30 and a 52-week high of $172.23. The company has a market cap of $49.24 billion, a P/E ratio of 19.38, a P/E/G ratio of 1.77 and a beta of 0.95. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The business has a 50-day simple moving average of $123.79 and a two-hundred day simple moving average of $129.67.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ZTS. UBS Group set a $136.00 price target on shares of Zoetis in a research note on Thursday, January 29th. Piper Sandler restated a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Weiss Ratings upgraded shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, March 12th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.